Other Services

ADMET and Pharmacokinetic Studies:
Hits from screening campaigns will be confirmed through sensitive biological assays to determine whether the compound is effective in inhibiting or activating the molecular target under study. We also provide pharmacokinetic data, including metabolic and chemical stability, membrane permeability, solubility, inhibition of major metabolic enzymes and mutagenicity.

Natural product Scaffolds:
Synthesis of natural product scaffolds and small set of (20-40) optimized libraries containing natural product scaffolds.

Building Block Synthesis:
Design and synthesis of building blocks/scaffolds with multiple reactive sites from milligram to multi grams

Lead Design:
Design and synthesis of optimized small targeted libraries for lead generation. Active Pharmaceutical Intermediates: Design and synthesize optimized small molecule libraries around API’s.

File enrichment libraries:
Generation of libraries of compounds according to customers file enrichment needs.

Solid phase synthesis:
Screening library synthesis on solid support.

Process optimization:
Expedite the transfer of process from bench top to poilet plants using combinatorial technology.
  CreaGen Inc. makes into the 2018 list of major players in CRO industry   more...
    7th Advances In Chemical Sciences Symposium: May 4th, 2018
The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception   more...
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.